<DOC>
	<DOCNO>NCT00325845</DOCNO>
	<brief_summary>The objective investigation evaluate safety efficacy viscosupplementation treat symptomatic lumbar facet joint arthropathy . The intend use device ( Synvisc ) alleviate pain improve function patient painful lumbar facet joint arthrosis intra-articular injection involve joint .</brief_summary>
	<brief_title>Synvisc Injections Lumbar Facet Joint Pain</brief_title>
	<detailed_description>Patients enter study putatively painful joint joint confirm single blind , double local-comparative anesthetic blockade . The joint ( ) suspect historical feature physical examination inject fluoroscopic guidance contrast-enhancement confirm intra-articular placement . The initial injectate 1cc 2 % xylocaine . Single diagnostic lumbar facet joint injection carry false positive rate 38 % . In order maximize specificity diagnostic injection second 1cc injection longer-acting local anesthetic , 0.5 % marcaine , perform patient report clinically significant pain reduction ( &gt; 75 % VAS reduction pre-injection baseline ) within 10-15 minute xylocaine injection . This second diagnostic injection complete upon return patient ’ pain back baseline ( sooner 3 day initial diagnostic injection ) . A true positive response define &gt; 50 % VAS reduction second injection . Patients undergo 2 IA Synvisc injection painful facet joint ( ) . An initial IA injection 1.0cc ( volume , exceed 1.0cc , accept joint upon reach capsular endpoint ) Synvisc ( 1cc , 10mg/ml ) inject painful joint ( ) 7 day second diagnostic injection baseline pain return . A 2nd injection perform 10 day initial injection . A 3rd injection may offer patient satisfied result obtain first 2 Synvisc injection . A 2.0cc vial Synvisc per patient ship include trial material investigator implementation . A fluid dispenser connector allow direct dispensation 1.0cc Synvisc pre-packaged 2.0cc unmarked vial . Outcome measurement tool include Visual Analogue Scale , Oswestry Disability Questionnaire , SF-36 , lumbar spine range motion ( ROM ) , sit walk tolerance , analgesic usage , patient satisfaction . Data collect baseline , 7-10 day second Synvisc injection , 1 , 3 , 6 , 12 month follow ( final Synvisc injection ) visit . For example , patient X undergo initial 2 Synvisc injection evaluate office 7 day later . If patient experience significant benefit , injection pursue . However , therapeutic benefit achieve satisfactory patient , 3rd Synvisc injection perform within 3 day . A side effect complication questionnaire complete patient within 30 minute , 24 hour , 72 hour injection ( include diagnostic injection ) .</detailed_description>
	<mesh_term>Arthralgia</mesh_term>
	<mesh_term>Hylan</mesh_term>
	<criteria>1 . Ongoing axial lumbar pain , great low limb pain present , &gt; 3 month duration . 2 . No improvement despite 68 week physical therapy ( PT ) , oral nonsteroidal antiinflammatory drug ( NSAIDs ) , relative rest , activity modification . 3 . Radiographic evidence facet joint arthrosis advance imaging study define joint capsule hypertrophy , osteophyte formation , joint space narrowing , irregularity joint contour , subchondral sclerosis , synovial cyst formation . 4 . Age 30 year old . 5 . Positive double , local comparative anesthetic diagnostic block injection one unilateral bilateral joint ( ) . 1 . Pregnancy . 2 . Active remote history spinal malignancy . 3 . Active infection . 4 . Blood dyscrasias/coagulopathy . 5 . Unwillingness follow follow evaluation . 6 . Negative response diagnostic facet joint injection . 7 . Application for/currently receive worker ’ compensation . 8 . Allergy avian product . 9 . Allergy prior viscosupplementation product . 10 . Prior viscosupplementation lumbar facet joint . 11 . Improper intraarticular needle placement time Synvisc injection . 12 . Painful bilateral multilevel facet joint arthropathy .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Investigational</keyword>
	<keyword>Therapeutic</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Outcomes</keyword>
	<keyword>Lumbar facet joint arthrosis</keyword>
	<keyword>Lumbar facet joint arthropathy</keyword>
</DOC>